Jeremy Anthony, MD
Endocrinology, Diabetes & Metabolism · Athens, GANPI 1487882056
Payments from drug & device makers
Across 52 payments — averaging $26.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$245
- Xeris Pharmaceuticals, Inc.$199
- Dexcom, Inc.$161
- Tandem Diabetes Care, Inc.$136
- Insulet Corporation$85
- Medtronic$72
- plus $464 from 15 others
What the payments were for
- Food & beverage$1,29195%
- Education$121%
- Gifts$594%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 11 | $245 |
| Xeris Pharmaceuticals, Inc. | 4 | $199 |
| Dexcom, Inc. | 3 | $161 |
| Tandem Diabetes Care, Inc. | 5 | $136 |
| Insulet Corporation | 4 | $85 |
| Medtronic | 4 | $72 |
| BETA Bionics, Inc. | 4 | $61 |
| Mannkind Corporation | 1 | $59 |
| Corcept Therapeutics | 2 | $43 |
| Novartis | 1 | $35 |
| Amneal Pharmaceuticals LLC | 2 | $30 |
| Cequr Corporation | 2 | $29 |
| Sanofi-aventis U.S. LLC | 1 | $28 |
| Neurocrine Biosciences, Inc. | 1 | $26 |
| Kyowa Kirin, Inc. | 1 | $25 |
| Lilly USA, LLC | 1 | $25 |
| Sequel Med Tech, LLC | 1 | $24 |
| Radius Health, Inc. | 1 | $23 |
| Boston Scientific | 1 | $20 |
| IBSA Pharma Inc. | 1 | $19 |
| Novo Nordisk | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RECORLEV$146
- DEXCOM CGM$119
How this compares
$1,362 in reported general payments places this provider in the 30th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CrysvitaBurosumab-Twza | 26 | $396,981 |
| OzempicSemaglutide | 184 | $209,068 |
| JardianceEmpagliflozin | 147 | $132,253 |
| TrulicityDulaglutide | 80 | $95,192 |
| MounjaroTirzepatide | 60 | $73,035 |
| Tresiba Flextouch U-200Insulin Degludec | 47 | $66,037 |
| FarxigaDapagliflozin Propanediol | 53 | $51,884 |
| JanuviaSitagliptin Phosphate | 40 | $44,154 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 37 | $44,049 |
| Tresiba Flextouch U-100Insulin Degludec | 30 | $38,506 |
| TradjentaLinagliptin | 25 | $32,621 |
| SynthroidLevothyroxine Sodium | 290 | $29,746 |
| Novolog FlexpenInsulin Aspart | 77 | $28,917 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $28,154 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 23 | $26,217 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Kyowa Kirin, Inc.Crysvita | $25 | $396,98126 claims |
| Novo NordiskOzempic, Fiasp, Novolog | $17 | $228,595222 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Baqsimi, Humalog | $25 | $180,132169 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $28 | $24,32947 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $30 | $7,368668 claims |
| IBSA Pharma Inc.Tirosint | $19 | $6,33726 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
Other endocrinology, diabetes & metabolism in Athens
- Malek MushrefAthens$9K
- Bruce BodeAtlanta$18.3M
- Gulliermo UmpierrezAtlanta$6.6M
- John ReedRoswell$5.7M
- Thomas JonesMacon$4.8M
- Steven LeichterColumbus$3.1M
- Jason BernerJasper$2.6M
- Ashwini GoreMacon$2.6M
- Adeniyi OdugbesanLawrenceville$1.8M
- David RobertsonAtlanta$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.